DaVita Inc. (NYSE: DVA), a leading global provider of kidney care services and a Fortune 500 company headquartered in Denver, Colorado, executed a significant capital markets transaction on June 8, 2026. On that date, the Company entered into a Ninth Amendment to its existing Credit Agreement originally dated August 12, 2019, with JPMorgan Chase Bank, N.A. as administrative agent, collateral agent, and swingline lender, among other parties. This amendment, which provides for $500 million in incremental borrowing under a senior secured term loan facility designated as the Tranche B-2 Term Facility, reflects the Company's ongoing efforts to optimize its capital structure, manage its debt maturity profile, and maintain financial flexibility in a dynamic healthcare environment. For a company that operates over 3,000 dialysis centers across the United States and serves patients in 11 countries internationally, effective capital management is essential to supporting the substantial capital expenditures required to maintain and expand its treatment infrastructure. The transaction, disclosed via a Form 8-K filing with the Securities and Exchange Commission, carries significant implications for DaVita's direct financial obligations, liquidity positioning, leverage profile, interest expense trajectory, and ongoing compliance landscape that merit careful examination by investors, creditors, and other stakeholders.

I. Terms and Structure of the Definitive Agreement

On June 8, 2026, DaVita Inc. entered into a Ninth Amendment (the "Ninth Amendment") to its existing Credit Agreement originally dated August 12, 2019. The counterparties to this amendment include DaVita as the borrower, its subsidiary guarantors, the lenders party thereto, and JPMorgan Chase Bank, N.A., serving in multiple capacities as administrative agent, collateral agent, and swingline lender. The Ninth Amendment provides for an incremental borrowing of $500 million under the Tranche B-2 Term Facility, which is structured as a senior secured term loan "B" facility maturing in May 2031 [Item 1.01 - Material Agreement, ¶1]. The designation of this facility as a "Tranche B-2" facility indicates that it is additive to the Company's existing tranche of term loans under the Credit Agreement, expanding the total term loan B exposure while maintaining the same secured creditor hierarchy.

The Tranche B-2 Term Loans are denominated in U.S. dollars and bear interest at DaVita's election based on either (i) the Base Rate plus the Applicable Margin or (ii) Term SOFR plus the Applicable Margin. The Base Rate is defined as the highest of the Federal Funds Rate plus 50 basis points, the Wall Street Journal prime rate, or one-month Term SOFR plus 100 basis points. The Applicable Margin is 175 basis points for Term SOFR loans and 75 basis points for Base Rate loans [Item 1.01 - Material Agreement, ¶2-3]. This dual-rate structure provides DaVita with flexibility to select the lower-cost borrowing option based on prevailing market conditions and interest rate expectations over the life of the facility. Notably, the 175-basis-point spread over Term SOFR represents a competitive pricing level for investment-grade crossover credits in the syndicated loan market, reflecting DaVita's established credit profile and its long-standing relationship with the lender syndicate.

The proceeds of the Incremental Tranche B-2 Term Loans are allocated for three specific purposes: (i) to repay a portion of DaVita's outstanding senior secured revolving loan facility, which terminates in November 2030, (ii) for the payment of fees, commissions, and expenses incurred in connection with the Ninth Amendment, and (iii) for general corporate purposes [Item 1.01 - Material Agreement, ¶3]. This allocation strategy indicates that the primary objective of the transaction is not to raise new net debt for aggressive expansion or shareholder returns, but rather to refinance existing borrowings on different terms and extend the maturity profile of the Company's obligations. By using longer-dated term loan proceeds to pay down shorter-dated revolving borrowings, DaVita is effectively engaging in a liability management exercise that reduces refinancing risk and enhances balance sheet stability.

The Tranche B-2 Term Facility is structured as a senior secured obligation under the Credit Agreement, with subsidiary guarantors providing guarantees and JPMorgan acting as collateral agent, collectively indicating that the facility is secured by a pledge of collateral—likely including equity interests in material subsidiaries, accounts receivable, and other assets as defined in the underlying Credit Agreement. The Credit Agreement also contains customary representations and warranties, although the Form 8-K explicitly notes these were made solely for the benefit of the parties and should not be relied upon as characterizations of DaVita's actual condition or state of facts [Item 1.01 - Material Agreement, ¶1, ¶4]. This disclaimer is standard in SEC filings of this nature and serves to remind the public that such representations are negotiated terms between sophisticated parties rather than independent factual disclosures.

DaVita and its affiliates may from time to time engage certain of the lenders under the Credit Agreement to provide other banking, investment banking, and financial services, reflecting a broad-based financial relationship that extends beyond this single credit facility. The filing further notes that the description of the Ninth Amendment is not complete and is qualified in its entirety by reference to the full text of the amendment filed as Exhibit 10.1 [Item 1.01 - Material Agreement, ¶3-4]. Investors and analysts seeking the complete terms of the transaction, including the full covenant package, events of default, and collateral arrangements, are directed to review this exhibit in conjunction with the Form 8-K narrative.

II. Direct Financial Obligation and Capital Structure Impact

The $500 million incremental borrowing under the Tranche B-2 Term Facility, with its maturity date of May 2031, represents a material addition to DaVita's direct financial obligations under a senior secured credit facility. This transaction is reportable under both Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation) of SEC Regulation S-K, reflecting its significance to the Company's financial profile [Item 1.01 - Material Agreement, ¶1; Item 2.03, ¶1].

The Incremental Tranche B-2 Term Loans bear interest at the Company's election based on either (i) the Base Rate plus the Applicable Margin, or (ii) Term SOFR plus the Applicable Margin. The Base Rate is defined as the highest of the Federal Funds Rate plus 50 basis points, the U.S. prime rate, or Term SOFR for a one-month interest period plus 100 basis points [Item 1.01 - Material Agreement, ¶2]. The Applicable Margin for the Tranche B-2 Term Facility is 175 basis points for Term SOFR loans and 75 basis points for Base Rate loans [Item 1.01 - Material Agreement, ¶3]. To illustrate the economics: assuming a Term SOFR rate of approximately 5.00%, the all-in interest rate on the facility would be approximately 6.75% (5.00% + 1.75%), resulting in annual interest expense of roughly $33.75 million on the full $500 million drawn balance. Under a Base Rate scenario, assuming a prime rate of approximately 8.00%, the all-in rate would be approximately 8.75% (8.00% + 0.75%), producing annual interest expense of approximately $43.75 million. The actual interest cost will fluctuate with benchmark rates over the facility's term.

DaVita has applied or will apply the proceeds from the $500 million incremental term loan toward three primary uses: (i) repayment of a portion of its outstanding senior secured revolving loan facility, which terminates in November 2030; (ii) payment of fees, commissions, and expenses incurred in connection with the transaction and the Ninth Amendment itself; and (iii) general corporate purposes [Item 1.01 - Material Agreement, ¶3]. The repayment of revolving debt with longer-dated term loan proceeds effectively term-structures a portion of DaVita's short-term borrowing capacity, reducing reliance on the revolving facility while freeing up availability under that line for future operational needs, acquisitions, or working capital requirements. This is a classic refinancing maneuver aimed at reducing short-term balance sheet pressure and extending the Company's debt maturity runway while maintaining strategic flexibility.

From a leverage and liquidity perspective, this transaction likely maintains or incrementally improves DaVita's liquidity position by replacing revolving borrowings—which can be drawn and repaid flexibly—with term debt that has a fixed maturity through May 2031. While total debt outstanding may not increase materially if the proceeds were used largely to repay other debt, the shift meaningfully lengthens the maturity profile of the Company's obligations. Critically, the maturity of the new term facility (May 2031) extends beyond the November 2030 maturity of the revolving facility it partially replaces, thereby extending the weighted-average maturity of the Company's overall debt portfolio. This lengthening of maturities reduces the near-term refinancing risk that DaVita faces and provides the Company with greater visibility into its future debt service obligations. Additionally, by paying down the revolving line, DaVita preserves future borrowing capacity under that facility for working capital, strategic investments, or other corporate needs [Item 1.01 - Material Agreement, ¶3]. This preserved liquidity buffer is particularly valuable for a healthcare services company that must navigate the periodic reimbursement cycles of government payors such as Medicare and Medicaid, which can create timing mismatches between revenue recognition and cash collection.

In terms of interest expense, the Incremental Tranche B-2 Term Loans carry floating-rate pricing tied to SOFR (plus 175 basis points) or Base Rate (plus 75 basis points). This floating-rate structure means that DaVita's interest cost will vary directly with short-term benchmark rates, exposing the Company to interest rate risk. If the Federal Reserve holds rates steady or reduces them, DaVita benefits from lower interest expense; conversely, if rates rise, the Company faces higher interest expense on this facility. To manage this exposure, DaVita may utilize interest rate derivatives such as swaps, caps, or collars—a practice common among corporate borrowers with substantial floating-rate debt. The Company's overall capital structure, including any hedging arrangements, will determine the net interest rate sensitivity of its debt portfolio.

Importantly, the information described in Item 1.01 is incorporated by reference into Item 2.03, confirming that this transaction constitutes a direct financial obligation of the registrant under applicable SEC disclosure rules [Item 2.03, ¶1]. This incorporation by reference ensures that the detailed terms disclosed under Item 1.01 are also deemed disclosed under Item 2.03 for purposes of SEC reporting requirements. Overall, the Ninth Amendment and the associated $500 million incremental term loan represent a deliberate capital structure optimization by DaVita—using longer-dated, secured term debt to refinance existing revolving borrowings, reduce short-term balance sheet pressure, and support general corporate flexibility while maintaining access to liquidity for future needs.

III. Risk Factors and Compliance Considerations

The Ninth Amendment and the associated $500 million incremental borrowing under the Tranche B-2 Term Facility maturing in May 2031 introduce several risk factors and compliance considerations that stakeholders should evaluate alongside the financial benefits described above [Item 1.01 - Material Agreement, ¶1]. These considerations span covenant restrictions, ongoing compliance obligations, acceleration and cross-default mechanisms, and regulatory and tax implications that collectively define the legal and operational framework within which DaVita must operate under this facility.

Restrictive Covenants and Operational Flexibility

The Tranche B-2 Term Loans are senior secured obligations, with JPMorgan Chase Bank, N.A. serving as administrative agent and collateral agent [Item 1.01 - Material Agreement, ¶1]. The secured nature of this facility implies the granting of collateral interests that may restrict DaVita's ability to incur additional debt, make restricted payments (including dividends and share repurchases), or dispose of material assets without lender consent. These covenants are standard in senior secured credit facilities but represent an ongoing constraint on management's operational discretion. For example, a financial covenant requiring DaVita to maintain a minimum interest coverage ratio or a maximum total leverage ratio could limit the Company's ability to pursue large acquisitions or return capital to shareholders during periods of financial underperformance. Proceeds are being used to repay a portion of the Company's revolving loan facility, pay fees and expenses, and fund general corporate purposes—reflecting a capital structure managed within covenant limitations that govern leverage and liquidity [Item 1.01 - Material Agreement, ¶3]. The fact that this is the Ninth Amendment to a credit agreement originally dated August 12, 2019 reflects a long-standing lending relationship where terms have been periodically adjusted, potentially to maintain covenant compliance or restructure maturities in response to changing business conditions [Item 1.01 - Material Agreement, ¶1].

Conditions Precedent and Ongoing Compliance

The Ninth Amendment contains representations and warranties made for the benefit of the lenders, and the filing specifically cautions that these representations "should not be relied upon as characterizations of the actual state of facts or condition of the Company" [Item 1.01 - Material Agreement, ¶4]. Customary borrowing conditions likely included affirmations of no material adverse change since the last financial reporting period, absence of any event of default under the Credit Agreement, accuracy of previously delivered financial statements and other disclosures, and the absence of any litigation or regulatory action that could reasonably be expected to have a material adverse effect on the Company. These representations establish ongoing compliance obligations that DaVita must satisfy throughout the facility's term, requiring continuous monitoring of financial ratios, covenant headroom, and disclosure accuracy. Any failure to maintain these representations—for instance, if a material adverse change occurs—could result in a default under the facility, potentially triggering acceleration of the $500 million outstanding balance.

Acceleration Triggers and Cross-Default Provisions

Though specific events of default are not enumerated in the Form 8-K, standard credit agreements of this type typically include acceleration triggers tied to payment defaults (failure to pay principal or interest when due), covenant breaches (violation of financial or negative covenants), insolvency events (bankruptcy filings, insolvency proceedings), material judgments (uninsured judgments above a specified threshold), and cross-defaults to other material indebtedness (a default on other debt exceeding a threshold amount triggers a default under this facility). The introduction of cross-default provisions means that a default on any other material debt instrument could trigger acceleration of this $500 million facility, creating a cascading risk that DaVita must carefully manage through its enterprise risk management framework. The Company and its affiliates may also engage certain lenders for other banking and financial services, creating customary but noteworthy conflict-of-interest considerations that arise when a lender serves in multiple capacities across different transactions [Item 1.01 - Material Agreement, ¶3].

Regulatory and Tax Implications

The interest rate structure—Term SOFR plus 175 basis points or Base Rate plus 75 basis points—exposes DaVita to floating-rate benchmark risk, meaning that changes in short-term interest rates directly impact the Company's interest expense [Item 1.01 - Material Agreement, ¶2]. In a rising rate environment, this floating-rate exposure could materially increase DaVita's interest costs, compressing operating margins and reducing net income available to common shareholders. As a healthcare company heavily reliant on Medicare and Medicaid reimbursement for its kidney care services, DaVita's general corporate purposes use of proceeds may include working capital or strategic investments that interact with regulatory frameworks, including anti-kickback statutes, Stark laws, HIPAA privacy and security requirements, and other healthcare compliance regulations. Changes to government reimbursement rates for dialysis services—a perennial risk factor for the Company—could affect cash flows available to service this incremental debt. Tax considerations under Section 163(j) of the Internal Revenue Code regarding interest deductibility could also materially affect the after-tax economics of this borrowing, particularly if DaVita's adjusted taxable income levels constrain the amount of deductible interest expense in any given tax year. The full covenant package and events-of-default provisions are incorporated by reference to Exhibit 10.1 filed with this 8-K, and interested parties are directed to that exhibit for complete details [Item 1.01 - Material Agreement, ¶3].

Conclusion

DaVita Inc.'s entry into the Ninth Amendment to its Credit Agreement and the associated $500 million Tranche B-2 Term Facility represents a carefully calibrated capital markets transaction designed to optimize the Company's debt structure without materially increasing its overall leverage. By refinancing shorter-term revolving borrowings with longer-dated term debt maturing in May 2031, DaVita has extended its debt maturity profile, preserved revolver availability for future operational needs, and secured competitive pricing that reflects its standing in the syndicated loan market. However, this transaction is not without its risks—including secured debt covenants that constrain operational flexibility, floating-rate exposure that subjects the Company to benchmark rate volatility, cross-default and acceleration provisions that require vigilant compliance management, and tax and regulatory considerations that interact with the Company's position as a heavily regulated healthcare provider. For a company navigating the complex intersection of government reimbursement policy, healthcare regulatory oversight, and capital-intensive operations, the Ninth Amendment provides enhanced financial stability while introducing compliance obligations that will require disciplined oversight through the facility's term through May 2031. The full text of the amendment, filed as Exhibit 10.1 with the SEC, contains the complete set of terms and conditions governing this financing transaction, and stakeholders are encouraged to review that exhibit alongside this Form 8-K for a comprehensive understanding of DaVita's latest capital structure maneuver.